A phase II trial of ImmunotheRapy with single fRactIon non-ablative raDIAtion in previously untreated patients with stage IV NSCLC. (IRRIDIATE-Lung trial).

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Stage Iv Nsclc
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Be willing and able to provide written informed consent/assent for the trial.
    2. Histologically documented, metastatic NSCLC with no previous systemic therapy.
    3. At least 2 distinct measurable metastatic sites, which are 1 cm or larger; patients can have radiation to multiple measurable disease sites as clinically indicated, however, there must be at least 1 measurable non-radiated target lesion for response assessment.
    4. Agreeable to provide archival tissue for correlative studies; if no archival tissue available may obtain a exemption by the study team.

You may not be eligible for this study if the following are true:

    1. Participant is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
    2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
    3. Has a known history of active TB (Bacillus Tuberculosis).
    4. Hypersensitivity to pembrolizumab or any of its excipients.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.